

CONCORD HEALTHCARE GROUP CO., LTD.* /

美中嘉和醫學技術發展集團股份有限公司

ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 29 December 2023 (the “**Prospectus**”) issued by Concord Healthcare Group Co., Ltd. (the “**Company**”). Any discrepancies between totals and sums of amounts listed herein are due to rounding adjustments.

Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information

Stock code	2453
Stock short name	CONCORD HC GP
Dealings commencement date	9 January 2024*

*see note at the end of the announcement

Price Information

Final Offer Price	HK\$14.28
Offer Price Range	HK\$14.10 - HK\$16.40
Offer Price Adjustment exercised	No

Offer Shares and Share Capital

Number of Offer Shares	39,420,200
Number of Offer Shares in Public Offer	3,942,200
Number of offer shares in International Offer	35,478,000
Number of issued shares upon Listing	716,338,416

Over-allocation

No. of Offer Shares over-allocated	-
------------------------------------	---

No over-allotment option has been granted

Proceeds

Gross proceeds (Note)	HK\$ 562.92 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$ (96.56) million
Net proceeds	HK\$ 466.36 million

Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the Prospectus dated 29 December 2023.

ALLOTMENT RESULTS DETAILS

PUBLIC OFFER

No. of valid applications	1,638
No. of successful applications	1,638
Subscription level	1.99 times
Claw-back triggered	No
No. of Offer Shares initially available under the Public Offer	3,942,200
Final no. of Offer Shares under the Public Offer	3,942,200
% of Offer Shares under the Public Offer to the Global Offering	10.00%

Note: For details of the final allocation of shares to the Public Offer, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by name or identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFER

No. of places	113
Subscription Level	1.02 times
No. of Offer Shares initially available under the International Offer	35,478,000
Final no. of Offer Shares under the International Offer	35,478,000
% of Offer Shares under the International Offer to the Global Offering	90.00%

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the places and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the places and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	Number of shares held in the Company subject to lock-up undertakings upon listing	% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing	% of shareholding in the Company subject to lock-up undertakings upon listing	Last day subject to the lock-up undertakings
Shanghai Medstar Financial Leasing Company Limited / 醫學之星(上海)融資租賃有限公司 ¹	192,274,636 (Domestic Shares)	N/A	26.84%	8 July 2024 (First Six-Month Period) ²

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
				8 January 2025 (Second Six-Month Period) ³
Beijing Concord Medical Technology Co., Ltd. / 北京泰和誠醫療技術有限公司	68,402,300 (H Shares)	27.74%	9.55%	8 July 2024 (First Six-Month Period) ²
				8 January 2025 (Second Six-Month Period) ³
Tianjin Concord Medical Technology Co., Ltd. / 天津泰和誠醫療技術有限公司	28,115,800 (H Shares)	11.40%	3.92%	8 July 2024 (First Six-Month Period) ²
				8 January 2025 (Second Six-Month Period) ³
Shanghai Xinhe Enterprise Management Center (Limited Partnership) / 上海信荷企業管理中心 (有限合夥)	13,333,332 (Domestic Shares)	N/A	1.86%	8 July 2024 (First Six-Month Period) ²
				8 January 2025 (Second Six-Month Period) ³
Subtotal	302,126,068	39.15%	42.18%	

Notes:

- Immediately after the completion of the Global Offering, Shanghai Medstar, Tianjin Concord, Beijing Concord and Shanghai Xinhe will collectively hold 42.18% of the issued share capital of our Company. Shanghai Medstar is owned as to 98.19% by Ascendium Group Limited, a wholly-owned subsidiary of Concord Medical, and as to 1.81% by Shanghai Huifu Technology Development Co., Ltd., which is in turn owned as to approximately 99% by Dr. Yang. Tianjin Concord is wholly owned by Shanghai Medstar. Beijing Concord is directly wholly owned by Concord Hospital Management Group Limited, which is in turn directly wholly owned by Ascendium Group Limited. Dr. Yang, through his controlled entity, Morgancreek Investment Holdings Limited, is entitled to exercise approximately 73.2% of the voting rights at general meetings of Concord Medical. The general partner of Shanghai Xinhe is Shanghai Xinfu Enterprise Management Center (Limited Partnership), the general partner of which is Shanghai Huifu Technology Development Co., Ltd. Therefore, Dr. Yang, Morgancreek Investment Holdings Limited, Concord Medical, Ascendium Group Limited, Shanghai Huifu Technology Development Co., Ltd., Concord Hospital Management Group Limited, Shanghai Medstar, Beijing Concord, Tianjin Concord and Shanghai Xinhe are the group of Controlling Shareholders of the Company.*

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
2. The expiry date of the lock-up period shown in the table above is pursuant to the relevant Listing Rules.				
3. According to the PRC Company Law, the Shares held by the Controlling Shareholders prior to the Global Offering are also restricted from trading within one year from the Listing Date.				

Pre-IPO Investors (as defined in the “History, Development and Corporate Structure” section of the Prospectus)

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
CICC Jiatai Phase II (Tianjin) Equity Investment Fund Partnership (Limited Partnership) / 中金佳泰貳期(天津) 股權投資基金合夥企業(有限合夥)	120,000,000 (Domestic Shares)	N/A	16.75%	8 January 2025
Ningbo Xinyu Jiahui Enterprise Management Co., Ltd. / 寧波信鈺嘉慧企業管理有限公司	77,777,776 (Domestic Shares)	N/A	10.86%	8 January 2025
Zhuhai Gefei Yunnuo Equity Investment Fund (Limited Partnership) / 珠海歌斐雲諾股權投資基金(有限合夥)	35,466,666 (H Shares)	14.39%	4.95%	8 January 2025
CSPC NBP Pharmaceutical Co., Ltd. / 石藥集團恩必普藥業有限公司	28,195,488 (Domestic Shares)	N/A	3.94%	8 January 2025
Jiaxing Shengshi Equity Investment Partnership (Limited Partnership) / 嘉興盛識股權投資合夥企業(有限合夥)	14,715,560 (Domestic Shares)	N/A	2.05%	8 January 2025

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Suzhou Juepu Investment Center (Limited Partnership) / 蘇州覺普投資中心 (有限合夥)	10,933,334 (Domestic Shares)	N/A	1.53%	8 January 2025
Suzhou Shengshan Huiying Venture Capital Partnership (Limited Partnership) / 蘇州盛山惠贏創業投資企業 (有限合夥)	2,400,000 (Domestic Shares)	N/A	0.34%	8 January 2025
Changsheng Assets Co., Ltd. / 長生資產有限責任公司	13,333,334 (H Shares)	5.41%	1.86%	8 January 2025
Ningbo Meishan Free Trade Port Area Guofu Hengcheng Investment Partnership (Limited Partnership) / 寧波梅山保稅港區國富衡誠投資合夥企業(有限合夥)	11,200,000 (H Shares)	4.54%	1.56%	8 January 2025
Jinjiang Lingfu Jiazi Equity Investment Partnership (Limited Partnership) / 晉江領複甲子股權投資合夥企業 (有限合夥)	6,741,888 (H Shares)	2.73%	0.94%	8 January 2025
Ningbo Meishan Free Trade Port Area Fengchuan Hongbo Investment Management Partnership (Limited Partnership) / 寧波梅山保稅港區豐川弘博投資管理合夥企業 (有限合夥)	6,666,666 (H Shares)	2.70%	0.93%	8 January 2025
Jiaxing Lecheng Investment Partnership (Limited Partnership)	6,111,894 (H Shares)	2.48%	0.85%	8 January 2025

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Partnership) / 嘉興樂澄投資合夥企業(有限合夥)				
Gongqingcheng Jinhe Equity Investment Partnership (Limited Partnership) / 共青城金和股權投資合夥企業 (有限合夥)	4,588,622 (H Shares)	1.86%	0.64%	8 January 2025
Hainan Qianyuan Jiamei Consulting Partnership (Limited Partnership) / 海南乾原嘉美諮詢合夥企業(有限合夥)	3,008,932 (H Shares)	1.22%	0.42%	8 January 2025
Ms. TIAN Yuan / 田原	2,444,756 (H Shares)	0.99%	0.34%	8 January 2025
Subtotal	343,584,916	36.33%	47.96%	
<i>Note:</i>				
<i>The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.</i>				

Existing Shareholders (other than the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Shanghai Guanyou Enterprise Management Center (Limited Partnership) / 上海冠佑企業管理中心 (有限合夥)	14,383,300 (H Shares)	5.83%	2.01%	8 January 2025
Qingdao Jinshi Haorui Investment Co., Ltd. / 青島金石灝納投資有限公司	6,666,666 (H Shares)	2.70%	0.93%	8 January 2025
Hangzhou Lanhai Youfang Equity Investment Fund	6,666,666 (Domestic Shares)	N/A	0.93%	8 January 2025

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings</i>
Partnership (Limited Partnership) / 杭州藍海有方股權投資基金合夥企業 (有限合夥)				
Guangzhou Jinkang Shenyong Investment Co., Ltd. / 廣州金康腎友投資有限公司	3,490,600 (Domestic Shares)	N/A	0.49%	8 January 2025
Subtotal	31,207,232	8.54%	4.36%	
<i>Note:</i>				
<i>The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.</i>				

PLACEE CONCENTRATION ANALYSIS

Placees	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	7,977,600	22.49%	20.24%	7,977,600	1.11%
Top 5	30,955,800	87.25%	78.53%	30,955,800	4.32%
Top 10	35,457,400	99.94%	89.95%	35,457,400	4.95%
Top 25	35,460,400	99.95%	89.95%	35,460,400	4.95%

Notes

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	96,518,100	39.15%	302,126,068
Top 5	0	0.00%	0.00%	170,901,400	69.32%	376,509,368
Top 10	15,427,000	43.48%	39.13%	206,403,620	83.72%	412,011,588
Top 25	37,729,800	106.35%	95.71%	244,860,624	99.31%	450,468,592

Notes

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	0.00%	0.00%	96,518,100	302,126,068	42.18%
Top 5	0	0.00%	0.00%	131,984,766	563,565,998	78.67%
Top 10	0	0.00%	0.00%	170,901,400	628,131,526	87.69%
Top 25	34,763,600	97.99%	88.19%	241,894,424	709,281,816	99.01%

Notes

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, 1,638 valid applications made by the public will be conditionally allocated on the basis set out below:

Pool A			
NO. OF H SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR
200	957	200 H Shares	100.00%
400	134	400 H Shares	100.00%
600	157	600 H Shares	100.00%
800	37	800 H Shares	100.00%
1,000	68	1,000 H Shares	100.00%
1,200	20	1,200 H Shares	100.00%
1,400	11	1,400 H Shares	100.00%
1,600	8	1,600 H Shares	100.00%
1,800	4	1,800 H Shares	100.00%
2,000	51	2,000 H Shares	100.00%
3,000	61	2,400 H Shares	80.00%
4,000	21	2,800 H Shares	70.00%
5,000	15	3,200 H Shares	64.00%
6,000	27	3,600 H Shares	60.00%
7,000	7	4,000 H Shares	57.14%
8,000	6	4,400 H Shares	55.00%
9,000	3	4,800 H Shares	53.33%
10,000	26	5,200 H Shares	52.00%
20,000	5	10,000 H Shares	50.00%
40,000	3	18,200 H Shares	45.50%
50,000	2	22,000 H Shares	44.00%
60,000	2	26,000 H Shares	43.33%
80,000	2	34,000 H Shares	42.50%
100,000	4	42,000 H Shares	42.00%
200,000	2	80,000 H Shares	40.00%
300,000	2	111,000 H Shares	37.00%
Total	1,635	Total number of Pool A successful applicants: 1,635	

Pool B			
NO. OF H SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR
400,000	1	400,000 H Shares	100.00%
1,971,000	2	785,400 H Shares plus 1 out of 2 to receive additional 200 Shares	39.85%
Total	3	Total number of Pool B successful applicants: 3	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 29 December 2023 for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

No stabilizing manager will be appointed, and it is anticipated that no stabilization activities will be carried out in relation to the Global Offering.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to terms and conditions set out in the Prospectus. Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the other Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed "Underwriting — Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. on the Listing Date which is expected to be on 9 January 2024.

PUBLIC FLOAT

Immediately following the completion of the Global Offering, (i) no less than 16.73% of the total number of issued Shares will be held by the public and will satisfy the minimum percentage as prescribed in the waiver granted by the Stock Exchange from strict compliance with Rule 8.08 of the Listing Rules; (ii) the three largest public Shareholders do not hold more than 50% of the Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; (iii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company; and (iv) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, January 9, 2024, provided that the Global Offering has become unconditional and the right of termination described in “Underwriting — Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of share certificates or prior to the share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. on Tuesday, January 9, 2024 (Hong Kong time), it is expected that dealings in our H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, January 9, 2024 (Hong Kong time). The H Shares will be traded in board lots of 200 H Shares each, and the stock code of the H Shares will be 2453.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Hong Kong, January 8, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. YANG Jianyu as chairman and executive Director, Ms. FU Xiao, Mr. CHANG Liang and Mr. SHI Botao as executive Directors, Mr. WANG Lei and Mr. CHEN Hongzhang as non-executive Directors, and Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.

* *For identification purposes only*